The AB Rating Is the Whole Business Model: Why America’s Branded Generics Live or Die on One Orange Book Letter
In November 2014, the FDA changed two letters next to a drug’s name in a government database, and a $1.23
In November 2014, the FDA changed two letters next to a drug’s name in a government database, and a $1.23
On February 7, 2026, Hims & Hers pulled a $49 compounded copy of Novo Nordisk’s Wegovy pill off the market
Ro vs. Hims & Hers: What the Compounding Crackdown Actually Did Read Post »
The Short Answer A strategy team that wants to license, co-promote, or acquire a drug asset needs to answer four
In the fourteen months after Bristol Myers Squibb agreed to pay up to $14.4 billion for Karuna Therapeutics, its lead
In fiscal year 2021, 167 of the 199 patent settlements pharmaceutical companies filed with the Federal Trade Commission contained a
On June 4, 2026, the Supreme Court ruled 9-0 that Hikma Pharmaceuticals did not induce patent infringement by selling a
Enbrel’s first composition patent expired in 2010. The drug is still exclusive in the United States sixteen years later, and
Right now, a patent-tracking service will tell you that Eliquis’s original composition-of-matter patent, U.S. Patent 6,967,208, is set to expire
Generic imatinib entered the US market on February 1, 2016, at 96 percent of the price of branded Gleevec. Sun
The Specialty Pharmacy Margin Everyone Protects Disappears the Day a Generic Launches Read Post »
Sign in or create a free account to read this DrugPatentWatch article